Latest news
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…
The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award
Le professeur Peter Vogel nommé titulaire de la nouvelle chaire Debiopharm de philanthropie familiale à l’IMD
Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…
GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.